$8.04
arrow_drop_up2.68%Key Stats | |
---|---|
Open | $7.50 |
Prev. Close | $7.53 |
EPS | -1.71 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 7.50 | 7.97 |
52 Week Range | 3.89 | 8.44 |
Ratios | |
---|---|
EPS | -1.71 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
Zevra Therapeutics Expands Executive Leadership Team
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates